Reduced nucleus accumbens enkephalins underlie vulnerability to social defeat stress.
Analgesics, Opioid
/ pharmacology
Animals
Behavior, Animal
/ drug effects
Benzamides
/ pharmacology
Depression
/ metabolism
Disease Models, Animal
Dominance-Subordination
Enkephalins
/ metabolism
Mice
Mice, Inbred C57BL
Nucleus Accumbens
/ drug effects
Piperazines
/ pharmacology
Receptors, Opioid, delta
/ agonists
Stress, Psychological
/ metabolism
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
22
01
2019
accepted:
15
05
2019
revised:
24
04
2019
pubmed:
28
5
2019
medline:
7
7
2020
entrez:
28
5
2019
Statut:
ppublish
Résumé
Enkephalins, endogenous ligands for delta opioid receptors (DORs), are highly enriched in the nucleus accumbens (NAc). They are implicated in depression but their role in the NAc, a critical brain region for motivated behavior, is not fully investigated. To provide insight into enkephalin function we used a chronic social defeat stress paradigm, where animals are either categorized as susceptible or resilient to stress based on their performance in a social interaction test. Compared to controls, susceptible animals showed reduced enkephalin levels in the NAc. Such decrease in enkephalin levels is not due to a change in mRNA of its precursor protein, proenkephalin, in susceptible mice but is consistent with increased mRNA levels of enkephalinases in the NAc of susceptible animals. Systemic administration of enkephalinase inhibitors or NAc infusion of the DOR agonist, SNC80, caused a resilient outcome to CSDS. Both treatments increased phosphorylation of ERK, which was downregulated by social defeat stress. To further validate these results, we also used Q175 knock-in mice, an animal model of Huntington's disease in which enkephalin levels are reduced in striatum and comorbidity with mood disorders is common. Consistent with data in wild-type mice, Q175 animals showed reduced enkephalin levels in the NAc and enhanced susceptibility to a social defeat stress. Overall, our data implicate that depression-like behavior induced by social defeat stress arises from disrupted DOR signaling resulting from lowered levels of enkephalins, which is partly mediated through elevated expression of enkephalinases.
Identifiants
pubmed: 31132785
doi: 10.1038/s41386-019-0422-8
pii: 10.1038/s41386-019-0422-8
pmc: PMC6784997
doi:
Substances chimiques
Analgesics, Opioid
0
Benzamides
0
Enkephalins
0
Piperazines
0
Receptors, Opioid, delta
0
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide
156727-74-1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1876-1885Subventions
Organisme : NIMH NIH HHS
ID : R01 MH106500
Pays : United States
Références
J Neurol Neurosurg Psychiatry. 2001 Sep;71(3):310-4
pubmed: 11511702
Nat Neurosci. 2006 Mar;9(3):443-52
pubmed: 16491081
Brain Res. 1979 May 18;168(1):200-4
pubmed: 222395
Prog Neurobiol. 2007 Apr;81(5-6):253-71
pubmed: 17169479
Psychopharmacology (Berl). 2015 May;232(9):1555-69
pubmed: 25373870
Nat Rev Neurosci. 2013 Sep;14(9):609-25
pubmed: 23942470
Mol Psychiatry. 2020 May;25(5):1022-1034
pubmed: 30120419
Neuropsychopharmacology. 2018 Sep;43(10):2056-2063
pubmed: 29925886
J Neurosci. 1998 Mar 1;18(5):1923-33
pubmed: 9465017
Brain Res. 1988 Sep 13;460(1):161-7
pubmed: 2464402
Eur J Pharmacol. 1984 Jan 27;97(3-4):301-4
pubmed: 6584312
PLoS One. 2012;7(12):e49838
pubmed: 23284626
Nat Genet. 2000 Jun;25(2):195-200
pubmed: 10835636
Neuron. 2019 May 8;102(3):564-573.e6
pubmed: 30878290
Trends Neurosci. 2000 Oct;23(10 Suppl):S20-7
pubmed: 11052216
Neuropharmacology. 2009;56 Suppl 1:122-32
pubmed: 18675281
Science. 2006 Feb 10;311(5762):864-8
pubmed: 16469931
Eur J Pharmacol. 1989 Jan 10;159(2):175-80
pubmed: 2707306
J Neurosci. 2011 Sep 21;31(38):13346-56
pubmed: 21940429
Neuron. 2017 Dec 20;96(6):1327-1341.e6
pubmed: 29268097
Prog Brain Res. 2007;160:273-84
pubmed: 17499120
Anesthesiology. 2011 Dec;115(6):1363-81
pubmed: 22020140
Neuropharmacology. 2000 Jul 24;39(10):1707-19
pubmed: 10884553
J Neurosci. 2001 May 1;21(9):3242-50
pubmed: 11312309
Front Syst Neurosci. 2011 Jun 08;5:32
pubmed: 21713123
Stress. 2014 Jan;17(1):88-96
pubmed: 24090157
J Neurochem. 1981 Feb;36(2):506-12
pubmed: 7463074
Neuron. 2011 Aug 25;71(4):656-70
pubmed: 21867882
J Neurosci. 2002 Apr 15;22(8):3251-61
pubmed: 11943826
Nat Neurosci. 2012 Jun;15(6):816-8
pubmed: 22544310
Biol Psychiatry. 2015 Feb 1;77(3):212-222
pubmed: 25173629
J Neurosci. 2016 May 4;36(18):4993-5002
pubmed: 27147652
Cell. 2007 Oct 19;131(2):391-404
pubmed: 17956738
J Neurol Neurosurg Psychiatry. 2007 Sep;78(9):939-43
pubmed: 17178819
Neuron. 2016 Oct 5;92(1):214-226
pubmed: 27667004
Biol Psychiatry. 1988 Mar 15;23(6):637-41
pubmed: 3281718
FASEB J. 1997 Apr;11(5):355-64
pubmed: 9141502
Pharmacol Biochem Behav. 1995 Sep;52(1):145-52
pubmed: 7501657
Eur J Pharmacol. 2006 Feb 15;531(1-3):151-9
pubmed: 16442521
Neuron. 2010 Jun 24;66(6):896-907
pubmed: 20620875
Neuron. 2015 Sep 2;87(5):1063-77
pubmed: 26335648
Psychopharmacology (Berl). 2001 Dec;158(4):388-98
pubmed: 11797060
Biol Psychiatry. 1993 Jul 1-15;34(1-2):100-7
pubmed: 8373929
Front Pharmacol. 2013 Nov 08;4:137
pubmed: 24265618
Trends Pharmacol Sci. 2003 Apr;24(4):198-205
pubmed: 12707007
Biol Psychiatry. 2016 Sep 15;80(6):469-478
pubmed: 26858215
J Neurosci. 2008 May 28;28(22):5671-85
pubmed: 18509028
Neuroscience. 1996 Jun;72(4):1023-36
pubmed: 8735227
Psychopharmacology (Berl). 1997 Dec;134(4):387-91
pubmed: 9452181
J Neurosci. 2012 Feb 1;32(5):1875-83
pubmed: 22302826
J Neurosci. 2017 Jul 5;37(27):6527-6538
pubmed: 28576941
Nature. 1976 Apr 15;260(5552):625-6
pubmed: 1264229
J Neurosci. 2013 Nov 20;33(47):18381-95
pubmed: 24259563
Curr Pharm Des. 2012;18(2):220-30
pubmed: 22229560
Physiol Rev. 2009 Oct;89(4):1379-412
pubmed: 19789384
Proteomics. 2018 Apr;18(7):e1700408
pubmed: 29406625
Behav Pharmacol. 2015 Oct;26(7 Spec No):654-63
pubmed: 26110224
Brain Res. 1995 Nov 27;700(1-2):89-98
pubmed: 8624732
Nature. 2003 Oct 30;425(6961):917-25
pubmed: 14586460
Annu Rev Neurosci. 1984;7:223-55
pubmed: 6324644
Nature. 1996 Oct 10;383(6600):535-8
pubmed: 8849726
Front Neurosci. 2010 Jun 28;4:50
pubmed: 20631848
Neuron. 2006 Sep 7;51(5):549-60
pubmed: 16950154
Life Sci. 1992;51(3):211-7
pubmed: 1352028
PLoS One. 2013 Sep 11;8(9):e75099
pubmed: 24040390
Neurotherapeutics. 2014 Jan;11(1):153-60
pubmed: 24366610
Brain Res. 2010 Feb 16;1314:56-73
pubmed: 19782055
Eur J Pharmacol. 1978 Apr 15;48(4):465-6
pubmed: 565718
Front Mol Neurosci. 2018 Apr 06;11:100
pubmed: 29681795
Br J Pharmacol. 2006 Apr;147(8):864-72
pubmed: 16491101
J Neurosci. 2015 May 20;35(20):7927-37
pubmed: 25995477
Neuron. 2010 Jul 29;67(2):294-307
pubmed: 20670836
Trends Neurosci. 2013 Mar;36(3):195-206
pubmed: 23219016